肽纳米纤维与Toll样受体激动剂联合载体-佐剂系统增强强效CD8+ T细胞应答
本研究在小鼠中构建了由自组装肽纳米纤维递呈单纯疱疹病毒免疫优势抗原、联合Toll样受体激动剂组成的载体-佐剂系统,可诱导强效的效应性和记忆性CD8+ T细胞应答。疫苗诱导的CD8+ T细胞效应功能受TLR激动剂类型影响,CpG(TLR9激动剂)较gardiquimod(TLR7激动剂)产生显著更强的体内特异性细胞毒性,并呈产生同时分泌IFN-γ和TNF-α细胞更多的趋势。肽纳米纤维联合任一佐剂进行初免-加强免疫均可诱导HSV特异性CD8+记忆T细胞。
要点
- 肽纳米纤维联合TLR激动剂可在小鼠中诱导强效HSV特异性效应和记忆CD8+ T细胞应答。
- CpG较gardiquimod产生显著更强的体内特异性细胞毒性,双细胞因子阳性细胞呈更多趋势。
- 肽纳米纤维联合任一佐剂初免-加强均诱导HSV特异性CD8+记忆T细胞。
核心结论
- 肽纳米纤维与TLR激动剂组成的载体-佐剂系统可在小鼠中诱导强效的HSV特异性效应和记忆CD8+ T细胞应答,且效应功能受TLR激动剂类型影响。
研究设计与样本
- 在小鼠中评估由自组装肽纳米纤维递呈HSV免疫优势抗原并联合TLR激动剂组成的载体-佐剂系统。
主要发现
- CpG(TLR9激动剂)较gardiquimod(TLR7激动剂)产生显著更强的体内特异性细胞毒性。
- CpG组较gardiquimod组呈产生同时分泌IFN-γ和TNF-α的细胞更多的趋势。
- 肽纳米纤维联合任一佐剂初免-加强免疫均诱导HSV特异性CD8+记忆T细胞。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Improving CD8+ T cell responses activated by subunit vaccination is crucial for improving vaccine efficacy and safety. Here we report a carrier-adjuvant system composed of self-assembling peptide nanofibers presenting an immunodominant antigen from herpes simplex virus (HSV) and toll-like receptor (TLR) agonists that induces robust effector and memory CD8+ T cell responses in mice. The effector function of vaccine-induced CD8+ T cells was influenced by the type of TLR agonist. The use of CpG (TLR9 agonist) resulted in significantly greater specific in vivo cytotoxicity and trended towards more cells producing both IFN-γ and TNF-α compared to gardiquimod (TLR7 agonist). Prime-boost immunization with peptide nanofibers combined with either adjuvant resulted in development of HSV-specific CD8+ memory T cells further demonstrating the capability of the carrier-adjuvant system to induce strong HSV-specific CD8+ T cell responses. Inclusion of peptide epitope-nanofibers in protein-based subunit vaccines should increase the functional spectrum of the vaccine-elicited immune response and protection.
引用
- Rudra JS, Banasik BN, Milligan GN, et al. A combined carrier-adjuvant system of peptide nanofibers and toll-like receptor agonists potentiates robust CD8+ T cell responses. Vaccine. 2017. PMID: 29248267. doi:10.1016/j.vaccine.2017.12.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。